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Abstract
Topical corticosteroid formulations have been evaluated
by visual grading protocols for many years. Toward a
more objective methodology, several instrumental
methods have been evaluated for applicability in quan-
tifying the vasoconstriction side-effect that follows corti-
costeroid application to the skin. Although the chro-
mameter has been adopted by regulatory bodies
throughout the world as the current standard for topical
bioequivalence determinations, there is considerable
criticism of this instrument from several quarters. A pre-
liminary comparison reported here indicates that digital
image analysis provides statistically significant results
that are similar to those obtained by visual assessment
techniques, and shows considerably greater precision
than that obtained by the chromameter. Continued eval-
uation of objective assessment techniques, such as dig-
ital imaging, and continued modernisation of regulatory
bioequivalence requirements will assist in protecting pa-
tients and optimising clinical results.
Copyright © 2002 S. Karger AG, Basel
Introduction
Over the past 20 years it has become increasingly
obvious that incorporating the same drug, at the same
concentration, into different formulations of the same
type (pharmaceutical equivalents), seldom produces for-
mulations that are identical (or even similar) in drug
delivery potential. These formulations may have marked-
ly different clinical efficacies simply because of the differ-
ing potential of the vehicle to release the drug to the stra-
tum corneum. Considerable effort has, therefore, been
applied to the research of delivery vehicle optimisation
and maximisation of the thermodynamic leaving poten-
tial of drugs in topical formulations [1]. Additionally, the
(often marked) influence that the delivery vehicle itself
may have on the skin barrier is seldom considered (or
recognised) by researchers or clinicians [2]. An intricate
part of this modern research effort has been the need to
develop analytical systems capable of discriminating be-
tween the subtle drug delivery potentials of very similar
formulations – especially important in topical bioequival-
ence testing.
After 40 years of topical corticosteroid delivery re-
search and development, it is prudent to evaluate the sta-
tus of the fundamental science that underlies the assay
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methodologies commonly employed. As yet we do not
have answers to the following questions:
(1) What mass of a specific corticosteroid is required
for a clinical effect? Theoretically, changing from one
commercial product to a formulation judged to be equiva-
lent should not affect the clinical outcome for the patient.
In this respect, it is imperative to determine initially what
degree of change in topical drug delivery is required to
change the clinical response for the patient. Since much of
the currently applied drug is not absorbed from the
applied formulation (approximately 1% of the applied
drug is absorbed), the 80–125% parameter for equiva-
lence determination may not be appropriate for topical
products.
(2) Do we have optimised vehicles to deliver the drug
to the target site in the necessary concentrations? With the
modern sophistication now available for the design of top-
ical delivery vehicles (supersaturation, liposomes, pene-
tration enhancers), it is possible to deliver the same mass
of drug to the skin from much lower delivery formulation
concentrations than those presently on the market. Al-
most all presently marketed preparations are gross over-
doses [3, 4] of the drug in poorly designed delivery vehi-
cles, exemplifying the status of the science 30 years ago.
(3) Are regulatory laws current with scientific technolo-
gy? The emergence of the next generation of topical deliv-
ery vehicles may be hindered because of product registra-
tion regulations that are no longer applicable to today’s
technology.
The skin-blanching assay is unique in that the method-
ology utilises the localised vasoconstriction side-effect fol-
lowing topical corticosteroid application. The intensity of
the induced vasoconstriction has been used for 50 years
[5] to determine drug delivery to the skin, since the inten-
sity of the blanching has been shown [6] to be proportion-
al to the clinical efficacy of the formulation. McKenzie
and Stoughton [7] developed the first documented, single-
reading time, visual-assessment procedure for comparing
corticosteroid performance. This methodology has been
refined and improved over the decades [8–12] to the point
where the multiple-reading, visual-assessment protocol,
conducted by trained and experienced observers, is con-
sidered to be a highly sensitive and accurate tool in topical
corticosteroid delivery vehicle research.
However, in the face of increasingly sophisticated ana-
lytical systems employed in other spheres of pharmaceuti-
cal research, regulators have become increasingly weary of
the supposedly ‘subjective’ data generated by the visual
blanching assay protocol, and the resultant inability to
conduct inter-laboratory comparisons of results [13]. In
recent years, regulatory agencies have advocated the Mi-
nolta chromameter [14] for the quantification of the
intensity of the induced skin blanching. Although it was
believed this instrument could produce more objective
results than visual grading [15], the universal adoption of
this instrument has not been without controversy. Lately,
digital image analysis techniques have advanced dramati-
cally in sophistication and complexity, and their applica-
tion in clinical dermatology is now ubiquitous. It is clear
that this technology presents a viable alternative to the
subjective visual assessment protocol, and is superior in
accuracy and the precision of colour quantification to the
hand-held chromameter.
Visual Assessment
All variations of the vasoconstriction bioassay retain
one essential cornerstone: the intensity of the drug-
induced blanching side-effect must be quantified by some
means or other. The methodology of the visual assessment
assay, its sensitivity and reproducibility, have previously
been documented at length [8, 10, 11, 16]. The visual
methodology is routinely conducted for comparing two
formulations containing the same corticosteroid in the
same concentration [19], or for comparing different corti-
costeroids for clinical potency ranking [17]. This grading
system has substantial theoretical merit: the human eye is
an excellent discriminator of differences between very
similar colours. The visual system simultaneously com-
pares the skin colour of the application site with the sur-
rounding (unmedicated) skin, and the global visual assess-
ment subconsciously accounts for skin factors such as
inherent skin pigmentation, hirsutism and mottling.
These are fundamental facets of the assay that any instru-
mental/computational system would have to duplicate.
Refinements in visual assay methodology have mark-
edly improved its credibility. Observations that the inten-
sity of blanching produced by the same formulation
depends on the forearm position to which it is applied
[18], and varies between left and right arms, for example,
has prompted the suggestion that each formulation to be
compared should be applied to multiple sites, distributed
over the entire length of each arm. Formulations initially
judged to be equivalent by the single-point assessment
procedures were not considered so by subsequent, multi-
ple-point analyses [20].
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Chromameter Assessment
The perceived subjectivity of the visual assessment
procedure prompted the search for alternative corticoste-
roid test systems by the Food and Drug Administration
(FDA) [15]. These efforts culminated in the release of a
Guidance document [14] detailing the procedures to be
followed for the determination of topical corticosteroid
bioequivalence using the Minolta chromameter. This in-
strument analyses the light from a xenon source, incident
onto the surface to be measured, quantifying the reflected
light in terms of three colour indices: the a-scale (red-
green), the b-scale (yellow-blue) and the L-scale (light-
dark). These three values define a unique point on a three-
dimensional colour map, absolutely defining the colour of
the measured surface. The instrument performs accurate-
ly, precisely and reproducibly for solid, planar surfaces
that are completely uniform in colour and topography.
The Guidance [14] suggests the analysis of the a-scale
index data, in a protocol of pilot and pivotal trials with
corrections for baseline and unmedicated-site readings.
The a-scale values appear to show the greatest sensitivity
to change over the progression of the blanching response,
followed by the L-scale and b-scale data, respectively.
Since its introduction in 1995, there have been several
contentious publications in the literature concerning the
use of the chromameter for skin vasoconstriction mea-
surements [20–23]. For the purposes of determining a
dose-response relationship, the Guidance protocol con-
tends that different contact times – ranging from 15 min
to several hours – between (an arbitrarily decided mass of)
the reference formulation and the skin, parallels the dose
of corticosteroid delivered to the stratum corneum. How-
ever, topical drug delivery is not a linear phenomenon; the
vehicle typically changes markedly in composition after
application to the skin because of the evaporation and
penetration of constituents (i.e., the metamorphosis of the
vehicle), and the vehicle may markedly change the bio-
chemistry of the stratum corneum (both effects are time
and dose dependent) [2]. There may, therefore, be pro-
found changes in the thermodynamic activity of the drug
in the metamorphosing matrix or in the barrier potential,
with concomitant changes in the rate of drug delivery.
Depletion of drug from the applied formulation film,
extensive if the dose applied is small, may further con-
found the dose-response issue. The relationship between
formulation-skin contact time and the mass of drug that
penetrates the skin (reaching the dermal vasculature or
forming a reservoir in the stratum corneum), has not been
exhaustively evaluated. Recent developments in the field
of skin-stripping methodology [24] (dermatopharmaco-
kinetics) may be beneficial in helping to compare the
mass of corticosteroid residing in the stratum corneum
with the intensity of the induced vasoconstriction.
We have addressed the problems surrounding the cor-
rection of chromameter data for baseline and unmedi-
cated site values [23]; irrespective of the manner in which
these values are corrected (or not corrected at all), the
shapes and variability of the blanching profiles remain
essentially unchanged. However, potential problems of
the double-correction procedure are the propagation of
any errors from the time-zero baseline values throughout
the entire data set, and the introduction of greater vari-
ability. This manipulation often generated negative and
positive a-scale values for the measured response (nega-
tive values indicate greater blanching at the compared
unmedicated skin sites than at medicated sites, even when
vasoconstriction is clearly visible at the medicated sites).
The problem that arises from this observation consists of
selecting the appropriate method for the trapezoidal sum-
mation of the area under the effect curve (AUEC) for the
dose duration: should one subtract positive values from
negative values, calculate only the area under the abscissa,
or assume that positive values are zero for the purpose of
area computation? These different trapezoidal computa-
tion methods may lead to an appreciable variance in the
calculated AUEC response value – an integral component
of the response-modelling procedure used to estimate an
effective dose for 50% response (ED50) and dosing inter-
val values corresponding to half ED50 and twice ED50 (D1
and D2). The dose so established for ED50 is used as the
principal formulation contact time for the subsequent 40-
subject pivotal trial, while the vasoconstriction responses
resulting from the D1 and D2 doses are used as a screening
tool in the pivotal trial to exclude subjects from the data
pool in whom the ratio of these responses does not fall
within a Guidance-specified range. Furthermore, one
may also argue that it is inappropriate to model dose-
response data when the exact dose of drug generating a
specific vasoconstriction response cannot be determined.
Our experiences with the chromameter [20–24] have
demonstrated that the results obtained from skin mea-
surements (unlike measuring solid, homogeneous, planar
surfaces) are relatively imprecise and are not totally objec-
tive. Measuring forearm skin poses several problems:
(1) The operator should strive to achieve negligible but
intimate contact of the chromameter’s measuring head
with the skin. Although pressure is not a consideration
when measuring solid surfaces, dynamic changes may
take place in the microcirculation (and hence the colour)
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of the skin due to vasocompaction in response to the
superficial pressure from the measuring head.
(2) The angle at which the chromameter is presented to
the skin by the investigator is critical to the magnitude of
the masurement obtained. The measuring head should be
positioned perpendicularly to the application site, hence
the instrument analyses the reflected light from the mea-
sured surface. Although perpendicular positioning is not
problematic when measuring a solid object, it becomes
difficult when measuring a flexible, biological structure
like the forearm.
(3) Positioning of the 8-mm-diameter measuring ori-
fice of the hand-held probe is complicated by having to
look through the surrounding Perspex shroud. If the vehi-
cle application sites are small (typical of optimised proto-
cols), then even a relatively small offset in placement of
the head may result in a large discrepancy in the ‘aver-
aged’ data obtained. Larger application sites may solve
the positioning problem, but tend to induce vasoconstric-
tion that is marginally less intense, more diffuse and less
discriminating between similar formulations. It has been
our experience that these placement parameters, align-
ment and pressure are more closely controlled if the sub-
ject carries out self-assessment with the chromameter
probe than if this is carried out on the subject by an opera-
tor. However, this requires each subject to be fully trained
in chromameter operation.
(4) The presence of hairs, moles and skin mottling on
the arm can result in artefactual data since the darker
colours of these structures would be averaged with the
colour of the vasoconstricted skin.
(5) Anatomical and biological factors tend to confound
the data further. There is a circadian variation in the
intrinsic colour of the skin, which for the a-scale value on
the forearm tends to generate the largest numbers at night.
There is a definite gradient of skin colour between the
wrist and the elbow, maximal at the mid-forearm. There
is a difference in chromameter response along the inner
and outer sides of the forearm. Protocols must, therefore,
be designed in such a manner that all compared formula-
tions are represented randomly at multiple sites across the
entire forearm.
Other factors of concern, such as operator fatigue in
protocols that require several hundred readings to be tak-
en per hour in a topical availability trial involving a full
panel of subjects, are less scientific, but are important in
assessing the overall integrity of the data set. The inherent
objectivity of the instrument is reduced by the investiga-
tor’s subjective manipulation of the chromameter head,
resulting in data that have a marked variability. The val-
idity of the statistical modelling process, as discussed
above, is dependent on the quality of the assessment data
generated [20, 23]. The danger of such a data set is that
one may assign a condition of equivalence to exist be-
tween compared formulations, when, in reality, the as-
sessment methodology is not sufficiently precise to dis-
criminate statistically between the performance of the
dosage forms.
Digital Image Analysis
The technologies available for capturing, processing,
and analysing digital images have improved greatly in
recent years. Image analysis is already being applied to
dermatological diagnostic and lesion-monitoring pur-
poses; however, there does not seem to be widespread
application in formulation research and development yet.
Since the essential basis of the human skin-blanching
assay is the quantification of normal and medicated skin
colour, it seems logical that objective digital image analy-
sis should yield more accurate and precise descriptors of
these parameters than are currently possible with subjec-
tive visual assessment or the hand-held chromameter
measurement. Analytical software algorithms can auto-
matically identify the margins of colour regions in digital
images (identifying vasoconstriction sites) and can pro-
vide colour quantification of these sites using the usual
colour descriptors (R-G-B, L-a-b, etc.). On a less sophisti-
cated level, this process may be accomplished manually
by visual examination of the image and cursor delineation
of the blanching areas and surrounding unmedicated skin.
Advantageously, image analysis allows for exclusion of
overt skin blemish colour (e.g. nevi) or hair colour in the
overall analysis, a factor that may otherwise distort colour
analysis if incorporated into the ‘average colour’ calcula-
tion (e.g. chromameter). The major advantage of digital
image analysis is the size of the data set obtained, a 0.5-
cm2 skin site, even when captured at a relatively low reso-
lution, typically comprises several thousand image pixels
– each of which can be analysed for the composite colour
descriptors. A drug application site showing vasoconstric-
tion that is analysed in this manner may then be described
by mean and SD values for the colour mode co-ordinates
that are based on thousands of individual pixel measure-
ments. The greater accuracy, precision and validity of
these larger data sets appear to be highly advantageous
when compared with the single visual grading or single
chromameter values obtained for the entire incident mea-
suring area.
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Fig. 1. Mean (B SD) visual response grade
versus time profile for 3 corticosteroid for-
mulations from different potency classifica-
tions (1 observer, n = 6 sites per formula-
tion). Arrow pairs indicate statistically sig-
nificant differences (p = 0.05).
Experimental Comparison
A comparison of the different quantitation techniques
(visual, chromameter and digital image analysis) was per-
formed to estimate the usefulness of the latter in defining
the corticosteroid-induced skin-blanching response. The
overall objective of this preliminary study was to assess
the ability of the different techniques, when utilised in a
standard human skin-blanching assay performed as de-
scribed previously [8, 20], to make significant distinctions
between the vasoconstriction responses induced by three
formulations from different potency classes. One would
expect to obtain three response versus time profiles that
are significantly different from one another for the three
formulations tested, i.e. betamethasone 17-valerate (B
17V), fluocinonide (F) and clobetasol propionate (CP). If
a technique is to be used for bioequivalence evaluation
purposes, then the methodology must be able to discrimi-
nate accurately and precisely between formulations that
are known from clinical practice to be different from one
another, in other words, the sensitivity of the technique
must be proven. A quantification method that is not sen-
sitive enough to differentiate statistically between formu-
lations from different potency classes, cannot be applied
to the bioequivalence evaluation of pharmaceutical
equivalents.
A typical set of results are reported here for the evalua-
tion study in which the visual assessment was carried out
by an experienced, trained observer; the chromameter
analysis was conducted according to the FDA Guidance
suggestions [14], and digital images of each arm of each
volunteer were captured at each observation time at a rel-
atively low resolution of 60 pixels per cm. Adobe Photo-
shop (version 6.0) was used to analyse the digital images,
with manual delineation of blanching sites and a compari-
son of the pixel a-scale values at medicated sites with
those of the umedicated surrounding skin colour.
The non-parametric visual grades (0–4) recorded in
this study were processed as numerical data for the pur-
poses of this comparison, and are depicted in figure 1 as
the average skin-blanching response grade versus time
after formulation application to the skin. One standard
deviation is shown to indicate the variance of the data,
and pairs of arrows at each observation time indicate sta-
tistically significant differences between the mean data
points (p = 0.05, n = 6 forearm sites per preparation).
These results are similar to those obtained previously for
these three formulations in our laboratories, and show the
correct rank order for the formulations (the product that
is most effective clinically induces the greatest vasocon-
striction response and vice versa). Statistically, both CP
and F are significant different from B 17V, and CP is sig-
nificantly different from F at three observation times over
the period of maximal vasoconstriction. Therefore, when
the visual data are analysed in this form, there are signifi-
cant distinctions between the potencies of the three for-
mulations.
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Fig. 2. Mean (B SD) chromameter a-scale
response versus time profile for 3 corticoste-
roid formulations from different potency
classifications (n = 6 sites per formulation).
No statistically significant differences (p =
0.05) between the means at any observation
time. Data have been corrected for time-zero
skin colour values and for skin colour values
at unmedicated sites at each observation
time (FDA guidance methodology).
Fig. 3. Mean (B SD) digital imaging a-scale
response values versus time profile for 3 cor-
ticosteroid formulations from different po-
tency classifications (n = 6 sites per formula-
tion). Arrow pairs indicate statistically sig-
nificant differences (p = 0.05). Data have
been corrected for skin colour values at sur-
rounding unmedicated sites, at each obser-
vation.
The chromameter analysis of the skin-blanching re-
sponse is depicted in figure 2 and clearly demonstrates the
relatively poor precision of this instrumental data. Re-
markably, there is no statistical distinction between the
profiles of the different products at any observation time,
although the rank order of the response profiles is as
expected for the three products of different clinical poten-
cy. Therefore, here the chromameter is unable to differen-
tiate statistically between the three formulations from dif-
ferent potency classes.
The digital image analysis data depicted in figure 3 is
of clearly superior precision compared with the chro-
mameter data and the visual data. The larger data set used
for this quantitative analysis yields smaller standard de-
viations about the mean values, and there is a greater
overall number of statistically significant differences be-
tween the data points of the three response profiles. The
statistical differences here are similar to the visual data in
that both CP and F are significantly different from B 17V,
and CP is significantly different from F at three observa-
tion times over the period of maximal vasoconstriction.
Therefore, when the digital image data are analysed in
this form, there are significant distinctions between the
potencies of the three formulations.
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All three analytical methods (eye, chromameter and
digital analysis of images) produced the anticipated po-
tency rank order for the three formulations studied. How-
ever, quantitatively the precision of the data appears to
decrease in the following order: digital-imaging analysis 1
eye 1 chromameter. There are clearly more instances of
statistical significance in the digital imaging and visual
data than there are in the chromameter data. The former
methods would indicate significant differences between
products that are known from clinical experience to be
significantly different. Chromameter analysis alone
would not have made a clear distinction between the
products. It is presumed that the greater sensitivity of the
digital image analysis is due to the much larger data set
that is employed in the colour calculation of the medi-
cated and unmedicated skin. It is also assumed that the
delineation of the application site by cursor on the digital
image is more accurate than the physical placement of the
chromameter measuring head on the skin. Positioning
and manipulation errors may also, therefore, be reduced.
Discussion
One may well ask if it is prudent to define topical
equivalence determination protocols without knowing the
answers to the fundamental questions posed in the intro-
duction. Certainly, it is now known that pharmaceutical
equivalence (the same concentration of the same drug in
the same type of dosage form) is not required for pharma-
codynamic and clinical equivalence, and that the majority
of formulations on the market are not optimised in terms
of drug delivery. In many cases, one may speculate that
transdermal absorption occurs in spite of the delivery
vehicle composition, not because of it. At best, we are cur-
rently attempting to define product comparison experi-
ments that can show whether new products are ‘equal’ to
products already on the market – a process that does not
foster the incorporation of new delivery technology into
developed formulations. This process is exacerbated by
regulatory stipulations that generic equivalents should be
pharmaceutical equivalents. A broader recognition and
understanding of drug delivery may allow optimised vehi-
cles with smaller drug concentrations to be classified as
equivalents.
The visual assessment of corticosteroid-induces skin
blanching is subjective by its very nature. Scientifically, it
is highly preferable to have an objective method for the
measurement of corticosteroid-induced skin blanching
for bioequivalence evaluation purposes. However, the
proven reproducibility and accuracy of the visual assay
procedure provides the standard which objective tech-
niques must equate or surpass. Previous studies, and the
data presented here, indicate that digital image analysis
may be a more robust method for the quantitative analy-
sis of skin-blanching for bioequivalence testing purposes
than visual assessment or, especially, chromameter as-
sessment. Continued investigation, development and the
improvement in sophistication of these test systems will,
undoubtedly, produce reliable and robust protocols for
topical corticosteroid equivalence evaluation in the fu-
ture.
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